The Role and Prospects of Lenacapavir intermediate - CAS 2375019-85-3 in the Pharmaceutical IndustryLenacapavir Intermediate - CAS 2375019-85-3, also known as GS-6207, is a promising candidate for the treatment of HIV. It is a novel HIV capsid inhibitor that has shown great potential in clinical trials. Lenacapavir intermediate acts as a potent antiviral drug by inhibiting the viral replication of HIV-1 virus. This compound inhibits the viral replication by binding to the HIV-1 capsid protein and prevents viral packaging and maturation. In this article, we will explore different prospects of Lenacapavir Intermediate - CAS 2375019-85-3 in the pharmaceutical industry.1. Control of HIVLenacapavir intermediate has been shown to be effective in suppressing the HIV-1 virus in clinical trials. This compound suppresses the viral replication via an entirely different mechanism than currently available antiviral medications. Lenacapavir intermediate - CAS 2375019-85-3, as an HIV capsid inhibitor, has the potential to become the first-in-class drug for HIV-1 treatment.2. Unique Mechanism for HIV-1 SuppressionThe unique mode of action of Lenacapavir intermediate distinguishes it from other compounds that are currently available on the market. The compound prevents viral replication by interrupting the signal that triggers the packaging and maturation of HIV-1 virus in a host cell. This action helps to prevent the formation of a mature virion, leading to inhibition of viral replication.3. Potential Development as a Long-Acting TreatmentLenacapavir intermediate has excellent long-acting properties, which can provide effective results even with infrequent dosing. Its half-life ranges from 37 to 43 days, which is much longer than other available anti-retroviral medication. This makes this intermediate a potential long-acting HIV treatment option.4. Resistance ProfileOne of the significant challenges in HIV treatment is the development of drug-resistant strains. However, Lenacapavir intermediate - CAS 2375019-85-3 has shown to have a low resistance profile. Unlike other current anti-HIV agents that bind to the enzymes of the virus, Lenacapavir intermediate interferes with the capsid formation process making it difficult for the virus to develop resistance against it.5. Low Toxicity and Drug InteractionsLenacapavir intermediate has shown to have low toxicity, which reduces the risks of significant side effects. It also shows limited drug interactions, making it an ideal drug to use in combination with other HIV treatments.6. Potential for Combination TherapyLenacapavir intermediate is currently under examination for combination therapy with other HIV-1 medications. It may have an improved viral suppression rate as it works through a unique mechanism of action complementary to other HIV treatments.7. Importance of Active IngredientsThe active ingredient of Lenacapavir intermediate is especially important. It binds to HIV-1 capsid protein and blocks viral replication. As a result, it is important to obtain a high-quality active ingredient from a reliable supplier to create a successful pharmaceutical product.8. Formation and Properties of Lenacapavir IntermediateThe Lenacapavir intermediate - CAS 2375019-85-3 is a small white crystal powder, which has a molecular formula of C26H31N7O6. It has a molecular weight of 541.6 g/mol and a melting point of 259-261 ᵒC. These properties make it ideal for pharmaceutical development.9. Future ProspectsLenacapavir intermediate is still under clinical trials, but its potential as an HIV-1 treatment option is enormous. Its unique mode of action and advantageous physical properties make it a promising candidate for pharmaceutical companies. FDA is closely watching the clinical trials of Lenacapavir intermediate. The pharmaceutical industry is hopeful there will be an upcoming successful drug launch.Quote InquiryContact us!

Ravuconazole: A Powerful Antifungal AgentIf you are looking for an effective antifungal medication, Ravuconazole can be a great option for you. Ravuconazole, with its CAS number 182760-06-1, is a triazole antifungal medication that has been proven effective for the treatment of various types of fungal infections. In this article, we will discuss Ravuconazole in detail, including its uses, dosage, side effects, and more.What is Ravuconazole?Ravuconazole is a powerful antifungal medication that is used for treating fungal infections, such as aspergillosis, candidiasis, and cryptococcal meningitis. It is classified as a second-generation triazole antifungal agent and has a broad spectrum of activity against many types of fungi. Ravuconazole is available in both oral and injectable forms, making it easy for patients to use.How does Ravuconazole work?Ravuconazole works by inhibiting the biosynthesis of ergosterol, which is an essential component of fungal cell membranes. By disrupting this process, Ravuconazole prevents the growth and development of the fungal cell, leading to its death.What are the uses of Ravuconazole?Ravuconazole is primarily used for the treatment of various fungal infections. Some of the common infections it can treat include aspergillosis, candidiasis, and cryptococcal meningitis. It is also effective against some rare and severe fungal infections that can affect the lungs, skin, and nails. Additionally, Ravuconazole has been used successfully in treating fungal infections in patients with weakened immune systems, such as those with HIV or undergoing chemotherapy.How is Ravuconazole administered?Ravuconazole can be administered either orally or by injection. The dosage and duration of treatment will depend on the type and severity of the fungal infection, as well as the patient's age and general health. For oral administration, the standard adult dosage is usually 200-300mg once daily, while for injection, the dose is typically 6mg/kg once daily. It is important to follow the instructions of your doctor or pharmacist when using Ravuconazole to ensure optimal treatment outcomes.What are the side effects of Ravuconazole?Ravuconazole is generally well-tolerated by most patients, and side effects are relatively rare. However, as with any medication, some patients may experience unwanted side effects. The most common side effects of Ravuconazole include upset stomach, diarrhea, headache, and nausea. More serious side effects such as liver damage, skin rash, and allergic reactions are rare but can occur in some patients.What are the precautions when using Ravuconazole?Before using Ravuconazole, it is important to inform your doctor of any medical conditions you may have, as well as any medications you are taking, including over-the-counter medication and dietary supplements. Additionally, if you are pregnant or planning to become pregnant, or breastfeeding, you should discuss the use of Ravuconazole with your doctor.ConclusionRavuconazole, with its CAS number 182760-06-1, is an effective antifungal agent that can be used to treat a wide range of fungal infections. Its broad spectrum of activity, combined with its ease of use, makes it a popular choice among healthcare providers. With proper use and monitoring, patients can experience successful outcomes with Ravuconazole, improving their quality of life and overall health.Quote InquiryContact us!

The Importance of Efinaconazole | CAS No. 164650-44-6| CAS No. 164650-44-6 in the Treatment of Nail Fungal InfectionsIf you are suffering from nail fungal infections, Efinaconazole might be the solution you’ve been looking for. Efinaconazole is an antifungal medication and is commonly used to treat toenail fungal infections. Also known as CAS No. 164650-44-6, Efinaconazole is a topical drug that works by inhibiting the growth of fungus. In this article, we will discuss the different prospects of Efinaconazole| CAS No. 164650-44-6 in treating nail fungal infections.The Mechanism of Action of Efinaconazole | CAS No. 164650-44-6CAS No. 164650-44-6, or Efinaconazole, works by inhibiting the function of an enzyme called sterol 14α-demethylase. This enzyme is vital for the production of ergosterol in the cell membrane of the fungus. Ergosterol is an essential component of fungal cell membranes. If the production of ergosterol is inhibited, the fungal cells cannot maintain their membrane integrity, resulting in the fungal cell’s death.How to Apply Efinaconazole | CAS No. 164650-44-6Efinaconazole topical solution is applied to the infected toenail once daily. The solution should be applied to the entire toenail and the surrounding skin. It is essential to use Efinaconazole continuously for the full course of treatment, even if the symptoms improve, to ensure that the fungus has been eradicated entirely. Treatment typically lasts for 48 weeks.Efficacy of Efinaconazole | CAS No. 164650-44-6The efficacy of Efinaconazole has been demonstrated in numerous clinical trials. In a study comparing Efinaconazole with placebo, 17.8% of patients with toenail fungal infections who were treated with Efinaconazole showed complete cure, compared to only 3.3% in the placebo group. This study demonstrated that Efinaconazole is more effective in treating toenail fungal infections.Contraindications for Efinaconazole | CAS No. 164650-44-6It is important to note that Efinaconazole is contraindicated in individuals with a history of hypersensitivity to any of the components of the solution. Additionally, it has not been established if Efinaconazole is safe for pregnant or breastfeeding women.Interactions of Efinaconazole | CAS No. 164650-44-6 with other MedicationsThere are no known drug interactions associated with Efinaconazole. However, it is essential to inform your physician about all the medications you are taking, including prescription and non-prescription medications or supplements, before starting treatment with Efinaconazole.Storage Requirements for Efinaconazole | CAS No. 164650-44-6Efinaconazole should be stored at room temperature, away from light and moisture. The solution should be kept out of the reach of children. Additionally, the application brush should be cleaned and stored separately after each use to prevent contamination or re-infection.ConclusionEfinaconazole | CAS No. 164650-44-6 is a safe and effective medication for the treatment of toenail fungal infections. It works by inhibiting the growth of fungus, allowing the infected toenail to heal gradually. Although it may cause mild side effects, it is generally well-tolerated and can be used by most people. If you are suffering from toenail fungal infections, consult your physician, and ask if Efinaconazole is right for you.Quote InquiryContact us!

The Basics of Efinaconazole intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 is a pharmaceutical intermediate used in the synthesis of Efinaconazole, which is used to treat toenail fungus. Efinaconazole intermediate CAS 127000-90-2 is a crystalline solid with a molecular weight of 294.3 g/mol.Synthesis of Efinaconazole Intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 can be synthesized by condensation of 4-phenyl-2-butanone with 2-chloroethyl isocyanate in the presence of sodium hydride. The resulting product is then purified by crystallization to obtain the final product.Properties of Efinaconazole Intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 is a white crystalline solid with a melting point of 72-73 °C. It is sparingly soluble in water and soluble in most organic solvents. The product should be stored in a cool, dry place to prevent degradation.Applications of Efinaconazole Intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 is mainly used in the synthesis of Efinaconazole, which is an FDA approved drug for the treatment of toenail fungus. It is also used as a starting material in the synthesis of other pharmaceutical intermediates.Safety Considerations for Efinaconazole Intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 may be harmful if ingested, inhaled, or absorbed through the skin. It is important to handle the product with care and wear protective equipment such as gloves and a lab coat. Spills should be cleaned up immediately.Regulatory Status of Efinaconazole Intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 is not currently listed in any major regulatory databases. However, it is important to follow all local, state, and federal regulations regarding the manufacturing and handling of the product.Price and Availability of Efinaconazole Intermediate CAS 127000-90-2Efinaconazole intermediate CAS 127000-90-2 is available from a variety of chemical suppliers and may be purchased in bulk quantities. The price of the product varies depending on the quantity purchased and the supplier.Future Research and DevelopmentsFuture research in the field of pharmaceutical synthesis may lead to new and more efficient methods of synthesizing Efinaconazole intermediate CAS 127000-90-2 and other related intermediates. This could lead to improved efficiency and cost-effectiveness in the manufacturing process.Efinaconazole intermediate CAS 127000-90-2, toenail fungus, pharmaceutical intermediate, synthesis, properties, purity, safety, storage, regulatory status, price, availability, research, developments Complete Guide to Efinaconazole intermediate CAS 127000-90-2 Discover the synthesis, properties, applications, and safety considerations of Efinaconazole intermediate CAS 127000-90-2 in this comprehensive guide. Buy high quality products from reliable suppliers now! Efinaconazole intermediate, pharmaceutical synthesis, toenail fungus treatment, organic chemistry, chemical industry, pharmaceutical industryQuote InquiryContact us!

IntroductionLenacapavir, also known as Ibalizumab-uiyk, is a humanized monoclonal antibody that is used as an antiviral agent in the treatment of HIV-1 infection. It is designed to target the CD4 receptor on human T cells and prevent the attachment of the virus to the host cell. Lenacapavir | CAS#2189684-58-8has recently been approved by the US Food and Drug Administration (FDA) for treating HIV-1 in adults who have failed multiple antiretroviral therapies. This article will review the properties, mechanism of action, clinical trials, and future prospects of Lenacapavir.PropertiesLenacapavir is a subcutaneously administered drug with a half-life of approximately 17 days. The dose is 2000 mg every four weeks and is intended for use in combination with other antiretroviral agents. It has a molecular weight of approximately 147 kDa and is formulated as a sterile, preservative-free, and clear to slightly opalescent solution. Lenacapavir is classified as an IgG4 kappa monoclonal antibody and is produced by recombinant DNA technology.Mechanism of ActionLenacapavir binds to the CD4 receptor of host T cells, thereby blocking the entry of HIV-1 into the cell and preventing viral replication. Unlike existing antiretroviral agents, Lenacapavir works by a non-competitive mechanism and does not induce drug resistance. It has been shown to have a unique resistance profile that is distinct from other antiretroviral agents. Lenacapavir does not interact with the cytochrome P450 enzyme system and has no significant drug-drug interactions.Clinical TrialsThe safety and efficacy of Lenacapavir were assessed in a Phase 3 randomized, double-blind, placebo-controlled trial (TMB-301) involving 335 HIV-positive adults who had previously failed multiple antiretroviral therapies. The primary endpoint was the proportion of patients achieving viral suppression (<50 copies/mL) at week 26. The trial demonstrated that Lenacapavir, when used in combination with optimized background therapy, achieved a statistically significant higher rate of viral suppression compared to placebo. The most common adverse events were injection site reactions, diarrhea, and headache.Future ProspectsLenacapavir represents a promising addition to the arsenal of antiretroviral agents for the treatment of HIV-1 infection. It offers a new mechanism of action, a unique resistance profile, and a long-acting dosing regimen. The approval of Lenacapavir by the FDA is a significant milestone in the development of HIV therapeutics. Further clinical studies are underway to assess the use of Lenacapavir in novel regimens, including in combination with other long-acting agents. Lenacapavir has the potential to transform the treatment of HIV-1 infection and improve the quality of life for people living with HIV.ConclusionLenacapavir is a new antiretroviral agent that has recently been approved by the FDA for the treatment of HIV-1 in adults who have failed multiple antiretroviral therapies. It works by blocking the attachment of the virus to the CD4 receptor of host T cells, thereby preventing viral replication. The drug has a long half-life, a unique resistance profile, and a favorable safety profile. Lenacapavir has the potential to become a mainstay in the treatment of HIV-1 and improve the health outcomes of people living with HIV.Lenacapavir | CAS#2189684-58-8, antiretroviral therapy, TMB-301, FDA, viral suppressionLenacapavir: A New Antiretroviral Agent for HIV-1 TreatmentLenacapavir, recently approved by the FDA, is a new antiretroviral agent used in treating HIV-1 infection. This article reviews its properties, mechanism of action, clinical trials, and future prospects.- Lenacapavir mechanism of action- Long-acting antiretroviral agents- Lenacapavir clinical trials- Lenacapavir FDA approval- Antiretroviral therapy for HIV-1- Lenacapavir resistance profileQuote InquiryContact us!

The Basics of CAS Number 2375019-85-3CAS stands for Chemical Abstracts Service, which maintains a database of chemical substances. The unique number assigned to each chemical substance is known as its CAS registry number. 2375019-85-3 is a CAS number that belongs to a specific chemical compound. It is important to have accurate CAS numbers to ensure proper identification, tracking, and handling of chemicals.The Importance of CAS Number 2375019-85-3CAS number 2375019-85-3 is important because it identifies a specific chemical compound that may have various uses or applications. By looking up this CAS number in a chemical database, scientists, researchers, and other professionals can access detailed information about the chemical composition and properties of the compound. This information is crucial for safety, regulatory compliance, and research purposes.The Role of 2375019-85-3 in ResearchResearch studies often require the use or analysis of specific chemical compounds, including those with CAS number 2375019-85-3. These studies can range from drug discovery to environmental testing. In any case, having accurate identification of the chemical compounds is vital for accurate research results. Researchers can find useful information about 2375019-85-3 through scientific journals and online databases.The Potential Uses of CAS Number 2375019-85-3CAS number 2375019-85-3 corresponds to a specific chemical compound, and its potential uses may vary based on the nature of the compound. Some possible uses of 2375019-85-3 include as a pharmaceutical intermediate, an agricultural chemical, or a specialty chemical. Determining the potential uses and limitations of this compound is important for those involved in its production or handling.The Safety Considerations of CAS Number 2375019-85-3It is important to understand the potential hazards and safety considerations associated with CAS number 2375019-85-3. Safety data sheets containing information about the hazards of the compound, including toxicity, flammability, and reactivity, should be available for anyone who handles or works with the substance. Proper safety protocols, such as wearing protective clothing and using ventilation, should be followed to prevent accidents or injuries.The Environmental Impacts of CAS Number 2375019-85-3CAS number 2375019-85-3 may have an impact on the environment, depending on its properties and uses. For example, it may affect water quality if it is released into a waterway. It is important to understand the potential environmental impacts of the compound and take necessary precautions to minimize them. Industries that produce or work with 2375019-85-3 should be aware of environmental regulations and strive to apply sustainable practices wherever possible.The Importance of Proper Labeling of CAS Number 2375019-85-3To ensure proper handling and communication of information about CAS number 2375019-85-3, it is crucial to have accurate labeling of the compound. This includes labeling the container or package with the correct CAS number, chemical name, and other pertinent information. Proper labeling can help prevent mistakes or accidents during transport, storage, and use.The Storage and Handling of CAS Number 2375019-85-3The storage and handling of any chemical substance, including 2375019-85-3, should follow proper protocols to ensure safety and regulatory compliance. This may include using designated storage areas, labeling containers with hazard information, and following proper disposal procedures. Those who handle or work with 2375019-85-3 should receive proper training and follow established safety guidelines.The Regulatory Requirements of CAS Number 2375019-85-3CAS number 2375019-85-3 may be subject to various regulatory requirements, depending on its uses and properties. Industries that produce or use the substance should be aware of relevant regulations from government agencies such as the Environmental Protection Agency (EPA) or Occupational Safety and Health Administration (OSHA). Compliance with these regulations is important for safety and environmental protection.The Future of CAS Number 2375019-85-3The future of CAS number 2375019-85-3 may be influenced by developments in technology, regulations, and demand. As more is learned about the properties and potential uses of the compound, new applications may arise. However, increased regulations or safety concerns may also influence its production or use. Keeping up with developments and trends related to 2375019-85-3 can help professionals make informed decisions about its use.Quote InquiryContact us!

Synthetic Overview of [CAS No. 110351-94-5] Exatecan Intermediate[CAS No. 110351-94-5] Exatecan Intermediate, a synthetic derivative of camptothecin, is widely used as an intermediate in preparing Exatecan mesylate, the anti-tumor drug. This intermediate is a key precursor used during the synthesis of Exatecan mesylate, which helps in treating various cancer types such as ovarian, prostate, lung, and breast cancer. Moreover, it improves the broader application scope of anticancer therapies.Chemical Properties of [CAS No. 110351-94-5] Exatecan IntermediateThe formula of [CAS No. 110351-94-5] Exatecan Intermediate is C26H28N2O5, with a molecular weight of 464.515 g/mol. Moreover, it's a white crystalline powder with a melting point of 216.2 °C – 217.8 °C, and a boiling point of 670.5°C at 760 mmHg. Furthermore, it's insoluble in water but soluble in DMSO, methanol, and chloroform.Potential Side Effects of [CAS No. 110351-94-5] Exatecan IntermediateThe use of [CAS No. 110351-94-5] Exatecan Intermediate as an intermediate in the preparation of anti-tumor drugs has some potential side effects such as nausea, anemia, and vomiting. In addition, it may lead to further side effects, including fatigue, diarrhea, and hair loss. Therefore, people are advised to take this compound under the supervision of a qualified doctor.Usage of [CAS No. 110351-94-5] Exatecan Intermediate[CAS No. 110351-94-5] Exatecan Intermediate is primarily used to prepare Exatecan mesylate, which is an anti-tumor drug used in different cancer types. This anti-tumor drug works by inhibiting the growth and replication of neoplastic target cells and brings various positive pharmacological responses. Moreover, this drug is indicated by healthcare practitioners for the treatment of various advanced and metastatic cancer types.Applications of [CAS No. 110351-94-5] Exatecan Intermediate[CAS No. 110351-94-5] Exatecan Intermediate is widely used in the commercial and medical industry for producing Exatecan mesylate, its derivative, an effective anti-cancer drug. Additionally, the broad-spectrum anticancer activity of this drug has made it an integral part of the pharmaceutical and medical industries. It is an essential compound for improving cancer treatment and promoting the overall health of patients.Preparation Process of [CAS No. 110351-94-5] Exatecan IntermediateThe preparation of [CAS No. 110351-94-5] Exatecan Intermediate involves several steps. These steps include the bisheteroannulation reaction of (E)-N-(1-cyano-1-methoxyimino-2-butenyl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide, which is reacted with N,N-dimethyl-N'-methylthioformamidine under the influence of a catalyst. This process results in the formation of Exatecan Intermediate. The compound is then isolated using standard techniques to achieve the desired purity.Future Scope of [CAS No. 110351-94-5] Exatecan IntermediateThe future of [CAS No. 110351-94-5] Exatecan Intermediate is bright, with increasing demand for anticancer drugs, the market growth of its derivatives, including Exatecan mesylate, is expected to increase rapidly in the coming years. Moreover, innovative drug development will benefit patients in the future by solving challenging medical conditions.ConclusionTo sum up, [CAS No. 110351-94-5] Exatecan Intermediate is a synthetic compound and useful precursor, which is essential in the manufacturing of the anti-tumor drug Exatecan mesylate. With a broad-spectrum anticancer activity, Exatecan mesylate has various indications in the treatment of multiple cancer types. Moreover, with increasing market demand for anticancer drugs, the market growth of Exatecan mesylate is showing an upward trend in the pharmaceutical industry.Quote InquiryContact us!

The Basics of 182182-31-6 | Exatecan Intermediate| Exatecan Intermediate182182-31-6, also known as Exatecan Intermediate, is an intermediate compound in the synthesis of the anticancer drug exatecan. It is classified as a heterocyclic compound and is used in the pharmaceutical industry.Synthesis of Exatecan IntermediateExatecan Intermediate is synthesized through multiple steps from starting materials, including amines and aldehydes. A key step in the synthesis is the condensation of an amine and an aldehyde to form a Schiff base, which is then cyclized to form a heterocyclic ring. The resulting compound is then converted into Exatecan through additional synthetic steps.The Properties of Exatecan IntermediateExatecan Intermediate is a yellowish solid that is soluble in some organic solvents. It has a molecular weight of 338.38 g/mol and a melting point of approximately 138-139°C. It is important to note that this compound should be handled with caution due to its potential hazards.Applications of Exatecan IntermediateThe primary application of Exatecan Intermediate is in the synthesis of the anticancer drug Exatecan. This drug has shown promising activity against multiple types of cancer, including breast, lung, and ovarian cancer. The synthesis of Exatecan is complicated and involves multiple steps, of which the creation of Exatecan Intermediate is one.Safety ConsiderationsAs with all chemical compounds, proper handling and caution should be exercised when working with Exatecan Intermediate. It is important to wear suitable protective equipment, such as gloves and goggles, when handling this compound. It should also be stored in a cool, dry place away from sources of heat and flame.The Future of Exatecan IntermediateAs research and development in the field of cancer treatment continues, there is a possibility that Exatecan and 182182-31-6 will play a larger role in cancer therapy. Additionally, further advancements in synthetic chemistry could lead to more efficient and cost-effective production of Exatecan Intermediate and the final drug product.Usage in ResearchExatecan Intermediate is also used in various research settings as a tool for investigating different biochemical pathways and identifying potential drug targets. Researchers can modify the chemical structure of Exatecan Intermediate to make derivatives that have different properties and functions, which can be used to probe the biological mechanisms underlying cancer and other diseases.Global Market OverviewThe global market for Exatecan Intermediate and Exatecan is currently small, but is expected to grow as the demand for cancer therapies increases. The market for Exatecan alone is projected to reach $352 million by 2025, with a compound annual growth rate of 10.8%.Conclusion182182-31-6, or Exatecan Intermediate, is an important compound in the synthesis of the anticancer drug Exatecan. It has potential applications in cancer therapy and is also used in research settings to investigate biological pathways. As with all chemical compounds, proper handling and caution should be exercised.Quote InquiryContact us!

IntroductionCAS 441045-17-6 Eribulin Mesylate is a synthetic derivative of Halichondrin B, a substance isolated from a marine sponge. It is used in the treatment of metastatic breast cancer and liposarcomas. Eribulin Mesylate belongs to the class of drugs known as microtubule inhibitors and works by stopping the growth of cancer cells.Chemical PropertiesEribulin Mesylate has the molecular formula C40H59NO11S and a molecular weight of 826.97 g/mol. It is a white to slightly yellow powder, soluble in water, dimethylsulfoxide, and methanol. The drug has a melting point of 208-215°C.PharmacokineticsEribulin Mesylate is administered intravenously and has a half-life of approximately 40 hours. The drug is metabolized by CYP3A4 and CYP3A5 enzymes in the liver, and the metabolites are excreted via the feces and urine.Therapeutic UsesEribulin Mesylate is primarily used in the treatment of metastatic breast cancer and liposarcomas. It has been shown to improve overall survival in patients with advanced/metastatic breast cancer who have received previous chemotherapy. Eribulin Mesylate is also being studied for use in other types of cancer, including non-small cell lung cancer and bladder cancer.Dosage and AdministrationThe recommended dose of Eribulin Mesylate for metastatic breast cancer is 1.4 mg/m2 intravenously on days 1 and 8 of a 21-day cycle. The drug is given until disease progression or unacceptable toxicity occurs.Side EffectsThe most common side effects of Eribulin Mesylate include fatigue, nausea, vomiting, constipation, fever, and headache. Other less common side effects include peripheral neuropathy, anemia, and neutropenia.Contraindications and PrecautionsEribulin Mesylate is contraindicated in patients with a history of hypersensitivity to the drug or its components. The drug should be used with caution in patients with hepatic or renal impairment. Eribulin Mesylate may cause fetal harm and should not be used during pregnancy.Drug InteractionsEribulin Mesylate may interact with other drugs that are metabolized by the CYP3A4 and CYP3A5 enzymes. The drug may also decrease the effectiveness of hormonal contraceptives.OverdoseIn the event of an overdose, Eribulin Mesylate should be discontinued, and supportive measures should be taken to manage symptoms. There is no specific antidote for Eribulin Mesylate.ConclusionEribulin Mesylate is an important drug in the treatment of metastatic breast cancer and liposarcomas. Its unique chemical structure and mechanism of action provide an effective treatment option for patients with these diseases.Quote InquiryContact us!